Enrofloxacin monohydrochloride (C09-1130-865)

Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC 90 of 0.312 μg/mL for Mycoplasma bovis . Enrofloxacin monohydrochloride shows inhibitory activity against vaccinia virus (VV).In VitroMycoplasma bovis is a worldwide pathogen, causative agent of pneumonia, mastitis, arthritis, and a variety of other symptoms in cattle. The antibiotic susceptibility profiles of the Hungarian strains are consistent within the tested group of fluoroquinolones. Three isolates (MYC44, MYC45 and MYC46) have high MIC values (≥10 μg/mL) to Enrofloxacin, while the rest of the strains are inhibited by Enrofloxacin with MICs ≤0.312 or 0.625 μg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoMice (n=80) undergo transient middle cerebral artery occlusion (MCAo) with reperfusion after 60 minutes. After MCAo, animals are randomly assigned to receive either a daily preventive medication (n=26, Enrofloxacin) starting at the day of MCAo or a therapeutic medication (n=25; Enrofloxacin) after diagnosis of lung infection. Standard treatment started immediately after the appearance of clinical signs (general health score>6) usually between day 4 and 6 after stroke. Both, preventive and standard antibiotic treatment using Enrofloxacin improve survival in a similar way compared with placebo treatment. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal administrationMice 11- to 14-week-old C57Bl6/J male mice are used. Enrofloxacin (2.5% oral solution) is dispensed in saline (2 mg/mL), antibiotic-treated animals receive a daily orally dispensed dose of 10 mg/kg body weight via feeding needle every 12 hours over a period of 7 days, while placebo animals receive the same amount of saline via feeding needle. Animals of preventive antibiotic group obtained Enrofloxacin after waking from reperfusion anesthesia (ca. 1 hour after operation). Therapeutic antibiotic treatment is given immediately after appearance of clinical signs (general health score>5) and confirmation of lung infection by MRI (signal rate≥5%). The group allocation is randomized . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Quinolone. Specification: 0.99 Molecular Formula: C19H23ClFN3O3 Molecular Weight: 395.86 EC Number: 688-293-7 PubChem CID: 45357113 Isomeric SMILES: CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl